Longeveron (LGVN) Interest Coverage Ratio (2020 - 2026)
Longeveron's (LGVN) quarterly Interest Coverage Ratio came in at 6.2 in Q1 2026, down 57.4% year-on-year from 14.56 in Q1 2025, and up 2.02% quarter-over-quarter from 6.33 in Q4 2025.
Longeveron (LGVN) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Longeveron's Interest Coverage Ratio history runs 7 years deep, the most recent figure standing at 6.2 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio fell 57.4% year-over-year to 6.2 in Q1 2026; TTM through Mar 2026 was 29.72, a 121.88% decrease from a year earlier, with the FY2025 full-year figure at 22.11, down 2311.2% from the prior year.
- Interest Coverage Ratio grew to 6.2 in Q1 2026 per LGVN's latest filing, from 6.33 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 436.75 in Q4 2022 and bottomed at 175.48 in Q4 2023.
- The 5-year median for Interest Coverage Ratio is 6.2 (2026), against an average of 2.17.
- Across the five-year window, Interest Coverage Ratio surged 529957.65% in 2022 and tumbled 14612.45% in 2024, its largest moves.
- Year by year, Interest Coverage Ratio stood at 436.75 in 2022, then plunged by 140.18% to 175.48 in 2023, then soared by 97.47% to 4.44 in 2024, then plunged by 42.67% to 6.33 in 2025, then rose by 2.02% to 6.2 in 2026.
- Per Business Quant, the three latest LGVN Interest Coverage Ratio figures stand at 6.2 (Q1 2026), 6.33 (Q4 2025), and 4.98 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | -6.20 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.20 |
| Dec 31, 2025 | -6.33 |
| Sep 30, 2025 | -4.98 |
| Jun 30, 2025 | -3.82 |
| Mar 31, 2025 | -3.94 |
| Dec 31, 2024 | -4.44 |
| Sep 30, 2024 | -20.75 |
| Jun 30, 2024 | -74.47 |
| Mar 31, 2024 | -18.26 |
| Dec 31, 2023 | -175.48 |
| Sep 30, 2023 | -23.04 |
| Jun 30, 2023 | -24.00 |
| Mar 31, 2023 | -0.12 |
| Dec 31, 2022 | 436.75 |
| Sep 30, 2022 | -23.16 |
| Jun 30, 2022 | -6.01 |
| Mar 31, 2022 | -4.83 |
| Dec 31, 2021 | 0.08 |
| Sep 30, 2021 | -0.27 |
| Jun 30, 2021 | -0.34 |